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Environmental health sciences focus on the
relationship between exposures to environ-
mental chemicals of concern and their rela-
tionship to health outcomes. The traditional
method for assessing human exposures to
environmental chemicals is to estimate, by
empirical or modeling methods, the concen-
trations of chemicals of potential concern in
environmental media (air, water, soil, food),
and then combine this information with esti-
mates of human exposure (e.g., estimates of
daily consumption of tap water) to determine
a dose. However, as analytic techniques have
evolved, there has been an increasing focus on
development and use of human biomonitor-
ing (i.e., measurements of levels of environ-
mental chemicals in human fluids such as
blood, urine, or milk, and in tissues such as
hair, nails, and fat) for evaluating exposure.
These data have often supplemented or even
supplanted estimates of exposure based on
environmental measures.
Biomonitoring has been used for several
decades for certain chemicals, such as for lead
in blood and cotinine in urine. More recently,
biomonitoring has provided data on levels of a
much wider array of chemicals in various
human ﬂuids and tissues. In the United States,
a systematic program of biomonitoring by the
Centers for Disease Control and Prevention
(CDC) has resulted in its National Report on
Human Exposure to Environmental Chemicals
(CDC 2003). This and other biomonitoring-
based research have produced a substantial
database on levels of environmental chemicals
in humans. However, important questions
remain: What is the relationship between these
internal levels and external exposures? What is
the baseline or “background” level against
which individual levels should be compared?
And how can internal levels be used to draw
conclusions about individual and/or population
health?
Uncertainties related to the relationships of
exposure with internal dose and of internal
dose with potential for adverse health effects
have been described by the CDC (CDC 2003)
and others (LaKind et al. 2005; Sexton et al.
2003; Stokstad 2004). These uncertainties
were also highlighted at a recent workshop on
environmental chemicals in human milk
(LaKind 2005), during which a multidiscipli-
nary group addressed questions regarding
interpretation of human milk biomonitoring
data for both the health of the mother and the
breastfeeding infant. Recognizing that individ-
uals from an array of disciplines have been
grappling with various aspects of biomonitor-
ing and that these disparate disciplines bring
different perspectives to the table, the Research
Foundation for Health and Environmental
Effects (RFHEE; a co-sponsor of the human
milk biomonitoring workshop) convened an
interdisciplinary panel for a 1-day workshop
on 13 November 2004 with the charge of
focusing on three speciﬁc aspects of biomoni-
toring: characteristics of scientifically robust
biomonitoring studies, interpretation of
human biomonitoring data for potential risks
to human health, and communication of
results, uncertainties, and limitations of bio-
monitoring studies. The RFHEE sought panel
members with expertise in medicine, toxicol-
ogy, epidemiology, biostatistics, and risk assess-
ment (the authors of this paper formed the
workshop panel). During the workshop, the
panel drew from the fields of medicine and
occupational health, which have a long history
of research on biomonitoring [National
Institute for Occupational Safety and Health
(NIOSH) 2004], as well as on the interpreta-
tion of the implications of biomonitoring
results for individuals. In this report, we
describe the recommendations reached during
the workshop regarding biomonitoring study
design, interpretation, and communication.
Recommendations of the
Workshop Panel
Biomonitoring Study Design
The design of any scientiﬁc study depends on
its goals and hypotheses. However, funda-
mental features that make for scientifically
robust and credible studies exist. The panel
focused on key research needs and recom-
mendations for ensuring that the goals,
hypotheses, and study design parameters are
realistic, transparent, and scientiﬁcally robust.
Investigators need to gain not only
approval but also acceptance for human stud-
ies. Biomonitoring studies involving human
subjects “must be conducted in a way that pro-
tects subjects’ rights and well-being,” and must
have the oversight of an institutional review
board (IRB), as described by the Common
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Harmonisation Good Clinical Practice guide-
lines, and the Declaration of Helsinki (LaKind
et al. 2005). Nevertheless, biomonitoring stud-
ies may prove controversial even when
approved by one or more IRBs. A recent exam-
ple is a U.S. Environmental Protection Agency
(EPA) study to monitor children’s exposure to
pesticides [the Children’s Environmental
Exposure Research Study (CHEERS);
CHEERS 2005]. Although the U.S. EPA
study involved monitoring rather than experi-
mental administration of pesticides and had
been approved by four separate IRBs, criticism
of the CHEERS study raised by nongovern-
mental organizations focused on payments of
up to $1,000 to subject families. This was criti-
cized as undue inducement; criticism was also
directed at partial industry funding of the
study (Environmental Working Group 2004;
Pesticide Action Network Updates Service
2004). In response, the U.S. EPA has cancelled
the study (U.S. EPA 2005). This example
highlights the need for thorough institutional
review of human biomonitoring studies and
the need for stakeholder acceptance, even after
IRB approval is complete. Recommendations
regarding ethical restrictions for biomonitoring
studies have been developed (Oleskey et al.
2004). Although these were developed for pes-
ticides, many of the recommendations have
broader applicability. Researchers should also
anticipate controversy from organizations and
individuals who may not accept the authority
of the IRBs to judge the ethical questions
raised by proposed research plans.
Because human tissue banking is a critical
component of biomonitoring studies, protocols
for ensuring sample integrity and access are
needed. Banking of human tissue/ﬂuid samples
is important for future hypothesis testing, but
it is complicated by cost, space, ethical consent
(especially for genomic studies), and Health
Insurance Portability and Accountability Act
regulations (HIPAA 1996). Proper long-term
storage conditions for specimens must be
determined. The most useful matrices (e.g.,
blood, urine, hair) should be targeted for stor-
age and should be linked to individual-level
data (e.g., questionnaires, health information).
In addition, to maximize the usefulness of such
a resource, a mechanism would be needed to
provide for future access to the specimens by
investigators not necessarily involved in the
original study.
Prioritization of chemicals selected for
biomonitoring studies should be health-based
but should also take into account factors such
as the ability to bioaccumulate, known expo-
sures in susceptible populations, analytic
capabilities, and ability to collect and analyze
the matrices that are most appropriate for
each chemical of concern. Put simply, chemi-
cals should not be measured in humans
merely because the analytic capability exists.
Prioritization should be based on criteria that
would yield the most useful data for maximiz-
ing public health gain.
An example of a model for prioritization
of chemicals for biomonitoring is the recently
awarded state biomonitoring program plan-
ning grant by the CDC to the state of New
Hampshire. New Hampshire was awarded this
grant for their proposal to develop biomoni-
toring programs to evaluate exposures to mer-
cury in ﬁsh, MTBE (methyl tert-butyl ether)
and arsenic in drinking water, and phthalates
from plastics. The rationale for selecting these
particular chemicals included several factors.
First, these chemicals were among the top 10
environmental chemicals of greatest public
health concern to that state’s population (New
Hampshire has high levels of arsenic in drink-
ing water and high levels of mercury in fish,
and recognizes the growing incidences of
MTBE groundwater contamination and
expanding database on phthalate exposures in
the general population). Also, there were read-
ily available and validated methods for analysis
of these chemicals in the appropriate biologic
matrices in the population (arsenic and mer-
cury in nails, MTBE and phthalates in urine
or blood), which could be readily obtained,
stored, and analyzed. Finally, there were
known links to human health effects at expo-
sures of concern (arsenic, mercury), and/or
there was growing concern about potential
health effects due to widespread or increasing
exposure (arsenic, mercury, MTBE, phtha-
lates) and potential for biomagniﬁcation in the
food chain or accumulation in humans (mer-
cury). Other chemicals of concern lacked one
or more of these key attributes: They were not
of unique or particular concern to New
Hampshire, were not known to bioaccumu-
late, lacked an appropriate, practical or cost-
effective methodology to analyze accurately,
required specialized matrices (e.g., fat biopsy)
that were impractical to obtain for a popula-
tion study, or there was little or no toxicologic
information to directly implicate them in spe-
ciﬁc health effects in humans. This selection
process serves as an excellent paradigm for
chemical selection for future biomonitoring
studies.
Collaborations among academia, industry,
and government should be encouraged to facili-
tate biomonitoring studies in occupational set-
tings. A critical component of any occupational
epidemiology study is the assessment of expo-
sure. Often industry has carried out its own
monitoring, including biomonitoring of the
workforce, as part of the routine assessment of
employee exposure, with results residing in ﬁles
or archives. However, investigators from out-
side the industry typically must rely on more
limited data for exposure estimation, such as
dates of employment, possibly obtained from
union records. Collaborations with industry,
built on mutual trust and respect, can often
mean the availability of more speciﬁc exposure
data. These can include biomonitoring results
as well as environmental monitoring results
and job-related data. For example, in a recent
cohort study of chlorpyrifos manufacturing
workers at the Dow Chemical Company, serial
measurements were made over the study
period of the chlorpyrifos urinary metabolite
3,5,6-trichloro-2-pyridinol and the intermedi-
ate end point, cholinesterase, allowing the
investigators to carefully characterize occupa-
tional exposures and examine potential associa-
tions with health outcomes (Albers et al.
2004). A potential drawback for extrapolating
these types of results (linking exposure to levels
in humans) to the general population is that
these occupational exposures may not be repre-
sentative of exposures that would be estimated
based on monitoring of air and other media, as
workers often use protective clothing or work
with largely enclosed processes.
The panel recommends that investigators
consider the following biomonitoring study
design issues:
Sampling frame. The extent to which
results can be generalized to a wider popula-
tion will depend almost entirely on the sam-
pling frame of the study. The best sampling
frame is a random selection from a clearly
deﬁned population (with a high level of par-
ticipation agreement), which will make results
almost entirely generalizable to that popula-
tion. The extent to which generalization from
the study population to the general popula-
tion will be restricted depends on whether
a) the population is self-selected (e.g., volun-
teers), b) there is a high degree of nonpartici-
pation, and c) participants are selected based
on specific characteristics or features (e.g.,
pregnant women).
Laboratory techniques. The laboratory
performing the analyses should conduct rigor-
ous quality assurance/quality control proce-
dures in accordance with accepted guidelines,
including calibration of instruments, running
appropriate standards and blanks, performing
spiking, blinded repeat and other quality assur-
ance measures, and reporting limits of detec-
tion, variation, and other statistical parameters
along with the experimental results (Needham
and Wang 2002; Needham et al. 2002).
Selection of human specimen type. In
selecting the matrix for a biomonitoring study,
the researcher must fully understand the utility
and quality of that matrix, as well as the bio-
logic signiﬁcance and complexity. This selec-
tion is often a balance between purely scientiﬁc
issues and the practicality of obtaining the
matrix for a population study in a cost-effective
way that is least invasive and risky to the study
participant. However, matrices such as urine or
blood, while easy to obtain or available from
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measurement of certain chemicals.
Integrity of samples. Improper collection,
transportation, and/or storage of specimens
can significantly affect the biomonitoring
results (Aitio and Jarvisalo 1985; Grifﬁn 1986;
Wax et al. 2000). Biomonitoring studies
should follow validated protocols that are
appropriate to the matrix and analyte(s) of
interest. Many samples require collection into
the appropriate storage container, clean tech-
niques for handling and storage, chemical or
physical stabilization of the sample, storage
under appropriate conditions, and control of
the number of times a sample is removed from
storage and assayed. Failure to follow these
steps can produce either degradation or specia-
tion change of the analyte or contamination of
the sample from external sources (Versieck
1985). For example, until the past decade or
so, it was not widely appreciated how easily a
sample can become externally contaminated
with chromium, principally from stainless steel
and other metal components, but also from
other sources. Simply dissecting and then
homogenizing a rat liver in a typical laboratory
blender can result in chromium contamination
many times the actual biologic level in the
sample. As a result, most published studies on
chromium levels in human and animal tissues
that did not recognize this problem contained
largely inaccurate data. Analysis of trace levels
of metals and other environmental chemicals
often requires full clean techniques including
metal-free, acid-washed sample collection and
storage procedures and special clean-room
analysis protocols. Likewise, collection of blood
into a typical vacutainer can highly inﬂuence
analysis of cadmium, plasticizers, and other
compounds that may leach from rubber stop-
pers and walls of containers. Investigators
should standardize and report their sample
protocols because this can be critical in inter-
preting and comparing results across studies.
Reporting of nondetects. The method
used to assign a value to analytic results below
the limit of detection (LOD; e.g., LOD/2)
should be described because the method cho-
sen can have an appreciable effect on the
results and their interpretation (Helsel 1990).
This is especially important in assessing popu-
lations in which biomonitored chemical con-
centrations are frequently below the detection
limit. Ideally, a sensitivity analysis should be
carried out to determine the effect that the
method of assigning values below the LOD
has on results and their interpretation.
Interpretation of Human
Biomonitoring Data
Carefully conducted human biomonitoring
studies serve several important functions,
including a) evaluating time trends for levels
of environmental chemicals in humans;
b) evaluating the efﬁcacy of regulatory action;
c) assessing regional differences in levels of
chemicals in populations; and d) establishing
baselines and distributions of body burdens
for populations. Biomonitoring information
lends itself well for such interpretation, partic-
ularly for studies that are representative of
populations of interest. However, besides
using biomonitoring data as a marker of
exposure, there is intense interest in using
these data as markers of health effect(s) and
establishing health-related reference levels for
the measured chemicals. Alcohol is an exam-
ple of a chemical for which exposure can be
linked to internal dose and internal dose can
be linked to effect. Lead is an example of an
environmental chemical for which exposures
are involuntary and for which there are sufﬁ-
cient data to draw associations between bio-
monitoring data and health, both to the
individual and to a population. Decades of
epidemiologic and toxicologic research on
lead effects provide the underpinnings for the
interpretation of blood lead level information.
Not only has interpretive information been
made available to the public for lead in chil-
dren’s blood, but advice on medical interven-
tions has also been developed. Both reference
levels and recommended clinical interventions
for other environmental chemicals are likely
to evolve over time as new information is
obtained; it is important to develop and make
available such interpretive documents for the
medical profession and the public.
Despite public pressure to provide more
immediate interpretations of biomonitoring
data in terms of potential for impacts on
health, the development of analytic methods
has provided the ability to measure extraordi-
narily low concentrations of a wide array of
chemicals for which there are insufﬁcient data
on which to base those interpretations. In
addition, it is often forgotten that the “meas-
urement of an environmental chemical in
a person’s blood or urine does not by itself
mean that the chemical causes disease” (CDC
2003, p. 2). The panel discussed several issues
related to interpretation of biomonitoring
data, described below.
To interpret biomonitoring data in terms
of health, studies are needed on the relationships
between exposure and levels in the body and
between levels in the body and health effect.
The ﬁrst critical step is to develop an under-
standing of the relationship between exposure
(applied dose) and body burden. This relation-
ship can be complex, as in the case of arsenic.
Although many toxic metals, such as lead, mer-
cury, and cadmium, accumulate in human tis-
sues such that biomonitoring can reveal the
extent of long-term cumulative exposure,
arsenic and other metals do not accumulate in
this way. Each metal has unique pharmaco-
kinetic and pharmacodynamic properties.
For arsenic, the exposure of concern is con-
sumption of inorganic arsenic in contami-
nated drinking water. Arsenic does not
bioaccumulate and is readily excreted by the
body with a half-life of days. As a result, total
arsenic levels in blood and urine are highly
variable. Moreover, because the inorganic
forms are of primary toxicologic concern, if
blood or urine analyses do not speciate arsenic
into its various forms, the resulting data often
have only limited toxicologic interpretative
value. In contrast, arsenic in nails can be an
excellent biomarker of exposure because it
principally measures inorganic arsenic expo-
sure, integrates exposure over several weeks, is
a highly stable matrix, and is relatively imper-
vious to external contamination or other con-
founders (Karagas et al. 1996, 2000, 2001a,
2001b; Nichols et al. 1998). Toenail arsenic
levels were shown to closely correlate with
drinking water arsenic at water levels > 1 ppb
(Karagas et al. 2000). More important, toxico-
logic end points of concern were actually
better correlated with toenail arsenic than
with drinking water arsenic levels, which indi-
cates that, in this particular situation, this bio-
marker provided a more precise internal
measure of individual exposure than com-
bining measures of external levels (drinking-
water arsenic) with estimates of exposure
(how much water consumed per day). Such
internal measures will also better integrate
potential individual differences in uptake, dis-
tribution, metabolism, and excretion. This
example highlights the many potential advan-
tages of a good biomarker of exposure but
also illustrates the importance of determining
the appropriate matrix and methodology and
the validation of this marker by comparison
to external measures of exposure.
The second important step for a validated
biomarker is to relate internal body burden, as
assessed by the biomarker, to one or more bio-
logic end points, such as changes in gene or
protein expression, alterations in enzyme func-
tion, and specific polymorphisms or other
genotype information. For example, individ-
ual arsenic toenail levels have been shown to
correlate with decreases in lymphocyte expres-
sion of several DNA repair enzymes (Andrew
et al. 2003a, 2003b). Such information not
only provides potential biomarkers of expo-
sure and effect but also provides direct support
for the hypothesis that arsenic inﬂuences can-
cer risk, at least in part, by suppressing DNA
repair and thereby increasing the risk from
exposure to other environmental agents of
concern such as sunlight (for skin cancer) and
cigarette smoke chemicals (for lung and blad-
der cancer) (Karagas et al. 2001a, 2001b,
2004).
To be able to interpret biomonitoring
data, laboratory reporting of clinical reference
levels must be harmonized. Even for some
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cholinesterase and butyryl cholinesterase,
reference levels have not been determined
across laboratories using a consistent method
(Wilson et al. 2002). There is widespread clin-
ical confusion regarding the interpretation of
reference levels, occurring most commonly
when appropriate reference values are not pro-
vided by a reporting laboratory.
A recent clinical case involving a 46-year-
old gardener with chronic malaise illustrates
this point. An attending physician ordered a
hair analysis for multiple mineral elements,
including mercury and 16 additional “nutrient”
elements. The gardener’s only reported expo-
sure was having previously worked in cleaning
laboratories at a nearby university where ele-
mental mercury was used in manometers and
other instruments. His hair mercury concentra-
tion was reported as 4.57 ppm, compared to
the diagnostic laboratory’s reference range of
0–0.6 ppm. However, the reliability of such
hair mineral analysis has been questioned
(Barrett 1985; Seidel et al. 2001; Steindel and
Howanitz 2001). Because of the reported
abnormality of the hair mercury analysis, a
repeat 24-hr urine was collected after a DMPS
(sodium salt of 2,3-dimercapto-1-propane sul-
fonic acid) chelation challenge. The urine mer-
cury level was 3.1 µg over the 24-hr period, or
0.83 µg/L (laboratory reference range was
reported as 0–4 µg/24 hr). The measured level
was similar to the mean level of urine mercury
(0.77 µg/L) reported from the most recent
National Health and Examination Nutrition
Survey (NHANES) study and well below the
90th percentile level (3.15 µg/L) (CDC 2003).
Urine mercury concentrations in humans
> 100 µg/L have been associated with minor
neurologic signs (Goldman et al. 2001), and
urine mercury levels > 300 µg/L usually are
associated with overt symptoms (Bates 1998).
None of these indications was present in the
cited case, but the confusion regarding the
appropriate reference range may have provoked
the decision to treat with DMPS. This case
highlights the need for clear and consistent
reference values for biomonitoring data on
environmental chemicals.
Even if data on both toxicity and levels of
environmental chemicals in laboratory ani-
mals are available for a given chemical, inves-
tigators should proceed with caution when
attempting to link such information directly
with human biomonitoring data and human
health effects. Because of species-speciﬁc varia-
tion in absorption, distribution, metabolism,
and elimination, it is difficult to interpret
measured levels of environmental chemicals
in humans on the basis of levels of chemicals
in laboratory animals. However, the goal is to
eventually link animal or other laboratory
data to human biomonitoring data in a way
that harmonizes these data sets for more accu-
rate and robust risk assessments. Currently,
the primary approach for linking laboratory
animal data to human health effects is via the
risk assessment process, which relies on esti-
mates of dose. The no observed adverse effect
level (NOAEL) or the lowest observed adverse
effect level (LOAEL) is used to establish a
“safe” dose for humans. For some chemicals,
human biomonitoring information can be
used in combination with physiologically-
based pharmacokinetic (PBPK) models to
estimate dose (the success of this method
depends on the properties of the environmen-
tal chemical and the availability of parameter
information for building the PBPK model).
In this way, biomonitoring data can serve as a
marker of exposure (Figure 1). However, this
is not equivalent to using biomonitoring data
as a biomarker of effect. As noted by Bernard
and Hermans (1997), biomarkers of early
health effects should be stable in the biologic
specimen, speciﬁc for the target tissue or cell,
and sensitive to level of exposure to an insult.
In an ideal world, it is desirable to have bio-
monitoring data serve as both biomarkers of
exposure (Figure 1, left arrow) and effect
(Figure 1, right arrow). The science is cur-
rently insufficiently developed for both of
these purposes for most chemicals.
Environmental chemicals are a part of the
public health spectrum. Because of the com-
plex nature of disease etiology, scientists will
need to obtain and analyze extensive amounts
of data to fully understand which environ-
mental chemicals, and at what levels in the
body, are linked to adverse health outcomes. A
key factor that is often overlooked is the inher-
ent genetic variability of the population,
which can profoundly influence disease risk
even given the same environmental exposures.
The study of gene–environment interactions
will require an integration of exposure assess-
ment (such as with biomonitoring) with
genetic susceptibility assessment (such as with
genetic polymorphism biomarkers). According
to Waters and Fostel (2004, p. 943),
Predicting potential human health risks from
chemical stressors raises three general challenges:
the diverse properties of the thousands of chemi-
cals and other stressors that are present in the envi-
ronment; the time and dose parameters that deﬁne
the relationship between exposure to a chemical
and disease; and the genetic and experiential diver-
sity of human populations and of organisms used
as surrogates to determine the adverse effects of a
toxicant.
Biomonitoring environmental chemicals is
principally a public health tool that is part of
the risk assessment framework and, with cer-
tain exceptions, is not yet informative as a
marker for clinical risk. Therefore, biomoni-
toring—especially the types of biomonitoring
studies focused on emerging chemicals of
concern for which there are limited epidemio-
logic and toxicologic data—is not generally
useful for predicting adverse health effects to
the individual. There may be cases, however,
where an individual has very high, clinically
relevant levels of a given chemical that could
be used to assess their individual risk. For
example, detection of high arsenic levels in
individuals in New Hampshire as part of
ongoing epidemiology and biomonitoring
studies has been used as the basis for interven-
tion in the form of suggestions for further
testing and analysis for those individuals, rec-
ommendations to remediate their water, and
providing additional resources for informa-
tion about health effects and remediation
options (M. Karagas, personal communica-
tion). However, it is important to note and to
convey to such individuals that estimates of
risk are based on population studies, whereas
individual risks will be highly influenced by
genetic background, other environmental or
occupational exposures, lifestyle factors, and
other individually variable factors.
Cardiovascular epidemiology provides a
clear example of the complexity of document-
ing the usefulness and limitations of newly
Bates et al.
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Figure 1. The continuum from exposure to adverse health effect. BBDR, biologically based dose response.
With existing toxicologic and epidemiologic databases, we can more readily begin at the internal dose
[identiﬁed by the star (e.g., biomonitoring data for environmental chemicals in blood)] and move along the
arrow to the left, by using models such as PBPK models to obtain information on dose (exposure). At pre-
sent, for most environmental chemicals, the greater challenge is to begin at the internal dose starting point
and move to the right to obtain information about target tissue dose, biologic effects, and disease. (Adapted
from Waters and Fostel [2004], with permission from the authors and from the Nature Publishing Group.)
Dose
Exposure Internal
dose
Target tissue
dose
Exposure models
PBPK models
BBDR models
Mode(s) of action
Genetic
susceptibility
Disease Early biologic
effects
Altered
structure-
function
System models
Disease models
Disease etiologyidentiﬁed markers for clinical risk. The obser-
vation of advanced and early-onset athero-
sclerosis in patients with homocysteinuria
prompted evaluation of plasma homocysteine
as a risk factor for atherosclerosis in the
broader population. An initial case–control
study evaluated the level of homocysteine in
patients with coronary artery disease compared
to normal controls and observed significant
differences in mean levels between the two
groups (Kang et al. 1986). This finding by
Kang et al. has been subsequently conﬁrmed
in other retrospective and cross-sectional stud-
ies (Braunwald et al. 2001). However, the
results from prospective studies have been less
consistent (Essebag et al. 2003). Some debate
whether modestly elevated plasma homocys-
teine is a consequence rather than a cause of
atherosclerosis (Christen 2000). Randomized
trials to test whether lowering homocysteine
levels will decrease risks of cardiovascular dis-
ease have shown some benefit in some sub-
groups of patients with preexisting coronary
disease. Ongoing research is evaluating the
association between homocysteine and stroke
and other neurologic outcomes (Huang 2004;
Wright et al. 2004).
For adequate interpretation of popula-
tion-based biomonitoring data, improved
population-based health data collection is
essential. Most countries have some form of
death registration which is usually available to
researchers. Some countries or local regions
have disease-specific registries, most com-
monly cancer and birth defect registries.
However, to make possible the interpretation
of biomonitoring data, other registries are
needed for health end points such as neurode-
generative and respiratory effects. Newly
developed registries should have a rigorous
quality assurance program to ensure com-
pleteness and accuracy of records.
Communicating Results of
Biomonitoring Studies
Researchers typically use the peer-reviewed sci-
entific literature as their primary method of
communication of their study design, results,
and interpretation. This method is excellent for
communicating with other researchers, espe-
cially those in similar disciplines. However,
individuals outside of those ﬁelds will not nec-
essarily seek out the same journals for informa-
tion. On occasion, the media will become
aware of an emerging scientiﬁc issue or publi-
cation, and a condensed and simpliﬁed version
of the information will appear in a form avail-
able to the general public.
The scientiﬁc community must recognize
the public interest in human biomonitoring
studies and recognize that this interest has an
effect on regulators, federal and state legisla-
tors, advocacy organizations, industry, and
clinicians (who frequently ﬁnd themselves on
the front lines attempting to address concerns
about the meaning of those studies for their
patients’ health). Thus, researchers should con-
sider venues in addition to the peer-reviewed
literature so that their studies are properly
communicated to relevant audiences. One risk
associated with failing to do so is the potential
misinterpretation of study conclusions by the
media and the public. Misinterpretation is
even more likely when communicating to a
public that needs to be better informed about
disease etiology and its multifactorial nature.
General information on best practices for risk
communication is available in the published
literature and from government agencies
[Agency for Toxic Substances and Disease
Registry (ATSDR) 2001; Fischhoff 1995;
National Research Council 1989; Sandman
1990]. Some key points from the workshop
follow.
Investigators should be able to communi-
cate epidemiologic concepts such as the differ-
ence between absolute and relative risk. For
example, in the pediatric condition known as
Reye’s syndrome, there is an approximately
4-fold increased relative risk associated with the
use of salicylates. But even following salicylate
use, Reye’s syndrome remains a rare condition
in absolute risk terms, with only 25 cases
occurring in the United Sates in 1989 (a popu-
lation incidence of 1.3 per million children
under 5 years of age; Forsyth et al. 1989;
MMWR 1991). Clinicians and scientists often
grapple with the best way to understand and
communicate risk, as has been demonstrated
with basic and well-accessed information such
as cancer risks (Woloshin et al. 2002).
Although the scientiﬁc community’s ability
to communicate statistics and other mathemat-
ical concepts needs improvement, a larger issue
is the striking lack of numeracy in the general
population (Steen 1990). This is the back-
ground reality against which ﬁndings are com-
municated. Moreover, even when scientists
attempt to communicate statistics accurately,
these data can be misconstrued or miscommu-
nicated by popular media and the web, or are
in a form that is difﬁcult for the general public
to understand and interpret (Schwartz and
Woloshin 2004; Woloshin et al. 2003).
Methods for communicating scientiﬁc infor-
mation to the public, especially pertaining to
human health risk, have been addressed previ-
ously, and researchers in the ﬁeld of biomoni-
toring should be familiar with this literature
(ATSDR 2001).
For biomonitoring studies addressing
health effects, investigators should distinguish
between statistically significant effects and
clinically signiﬁcant effects. Although the reg-
ulator or epidemiologist may be interested in
the former, for clinicians and the public in
general the latter is of primary interest. For
example, studies reporting on the effects of
polychlorinated dibenzodioxins, polychlori-
nated dibenzofurans, and coplanar polychlori-
nated biphenyls on breastfed infants provided
data on levels of these environmental chemi-
cals in the mothers’ milk samples and on
infant serum levels of triiodothyronine, thy-
roxine, thyroid-stimulating hormone, thyrox-
ine-binding globulin, and lymphocyte subsets
(Nagayama et al. 1998a, 1998b). Effects on
infant serum levels were noted, but no inter-
pretive information was given. While this
method of presenting study results is suffi-
cient for many scientists, for the lay audience
and others, additional information is desir-
able. For example, it is not clear whether
observable adverse health effects in the infants
would be anticipated or whether the serum
levels were within clinically normal ranges
(LaKind et al. 2004). A small biologic change
in a quantitative measure can be statistically
significant without necessarily indicating a
change that is physiologically or toxicologi-
cally significant in terms of adverse health
outcomes.
The development of an accessible Internet-
based site for human biomonitoring data
should be a high priority. This type of site
would allow scientists and others to share and
compare data obtained from biomonitoring
research (Waters and Fostel 2004). Progress
with this type of public database is being made
in the field of toxicogenomics, which has
witnessed the development of data-exchange
standards and guidelines for harmonization in
data collection (Waters and Fostel 2004). A
possible model for such a database is the
Chemical Effects in Biological Systems knowl-
edgebase (http://cebs.niehs.nih.gov). Models
for standard-setting include the Clinical Data
Interchange Standards Consortium (CDISC
2004) and the Standards for Exchange of
Nonclinical Data (SEND 2004). The database
for human biomonitoring studies should
include the research data and reference ranges
(both for population concentration data and
clinical reference ranges). This type of site will
require continual updating, which necessitates
a long-term commitment of resources.
An established architecture is needed to
communicate the meaning of individual and
population-based biomonitoring results. A
concerted effort is needed to educate clinicians
regarding the availability of expertise in inter-
preting human biomonitoring data. For most
environmental chemicals, it is inappropriate to
suggest that individuals consult their doctors
with questions about biomonitoring data.
Clinicians, especially general practitioners, are
often ill prepared to answer speciﬁc questions
regarding chemical exposures and health risks,
nor are there obvious or readily available
resources for them to obtain this information
at a level and in a form that they and their
patients can understand. One current option
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would likely refer them to a specialist from an
established network of clinical toxicologists.
Another available option is to contact an
ATSDR office or a Pediatric Environmental
Health Specialty Unit (PEHSU).
A nationwide effort is needed to inform
physicians of the availability of medical toxicol-
ogists, such as members of American College
of Medical Toxicology (American College of
Medical Toxicology 2005). Efforts have been
made to create electronic networks for rural
physicians, such as the Rural Physicians Health
Network, which links them to larger medical
centers and other sources of specialized infor-
mation that they can use both for specific
patient inquiries and for continuing education.
Such a network could be established to link
physicians more generally to clinical toxicolo-
gists and public health officials that would
allow them to tap into the growing knowl-
edge base from biomonitoring, epidemiology,
and similar studies. This could also provide
physicians with appropriate information
resources for deciding whether and how to
analyze specific environmental chemicals in
an individual, how to select the appropriate
sample matrix and laboratory, and how to
interpret the results.
Resources are the limiting factor in creat-
ing a robust and continuously updated data-
base of human levels of environmental
chemicals, linked to information that would
allow these levels to be interpreted in terms of
potential health effects. The panel recom-
mends that resources for this purpose be given
a high priority. The panel recognizes that the
resources required to build such a database
will be signiﬁcant. However, for protection of
public health, it is insufficient to develop a
biomonitoring database without the ability to
interpret that database. Therefore, the panel
recommends that funding agencies and orga-
nizations devote the resources necessary for
this endeavor.
Because current exposures to certain envi-
ronmental chemicals may be related to future
adverse health effects, the panel recommends
that an architecture be developed to support
long-term storage of human specimens and that
a process be established to provide for sharing
of specimens as part of future investigations.
In the shorter term, physicians and others
involved in health care require current infor-
mation on interpretation of human biomoni-
toring data. Resources such as the American
College of Medical Toxicology (2005) and,
for pediatric issues, the PEHSUs (ATSDR
2005) are available but are not yet widely
recognized. A concerted effort is required to
increase the visibility of these resources and
to develop additional resources for the effec-
tive communication of the interpretation of
biomonitoring data.
In addition to resources for health care
providers, there is a serious need for well-
written, multilingual articles for the lay audi-
ence on an array of topics that would assist in
improving the public’s ability to understand
human biomonitoring information, including
associated uncertainties and limitations. In
addition to written material (i.e., manuscript-
style documents), formats such as pamphlets,
posters, graphic narratives, and videos are useful
for reaching a wider audience.
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